Ashkon Software

   







 

ACUR - Acura Pharmaceuticals, Inc.


ACUR Stock Chart

ACUR Profile

Acura Pharmaceuticals, Inc. logo

Acura Pharmaceuticals, Inc. (ACUR) is a pharmaceutical company focused on the development and commercialization of abuse-deterrent formulations of opioid analgesics and other drugs. The company's products utilize its proprietary Aversion and Impede technologies to deter abuse and misuse.

Acura Pharmaceuticals' lead product is Oxaydo, an immediate-release formulation of oxycodone that utilizes the company's Aversion technology to deter abuse through the use of inactive ingredients that make it difficult to crush, snort, or inject the drug. The company also has a pipeline of abuse-deterrent products in development, including hydrocodone, hydromorphone, and morphine formulations.

The company has reported financial results for the third quarter of 2021, reporting revenues of $1.2 million, compared to $1.5 million in the same period in the previous year. Acura Pharmaceuticals reported a net loss of $2.8 million for the quarter, compared to a net loss of $2.7 million in the same period in the previous year.

Acura Pharmaceuticals has been focused on advancing its pipeline of abuse-deterrent products and entering into partnerships and collaborations with other companies. In December 2021, the company announced that it had entered into a licensing agreement with Nuvo Pharmaceuticals to commercialize its immediate-release abuse-deterrent oxycodone product in Canada.

However, the company's financial performance and operations may be impacted by various factors, including the outcome of clinical trials, regulatory changes, and competition in the pharmaceutical industry. In addition, the ongoing opioid epidemic and public concern about the abuse and misuse of prescription drugs may affect the market for Acura Pharmaceuticals' products.

Overall, Acura Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of abuse-deterrent formulations of opioid analgesics and other drugs. The company has a pipeline of abuse-deterrent products in development and has entered into partnerships and collaborations to advance its research and development efforts. However, the company's financial performance and operations are subject to various risks and uncertainties associated with the pharmaceutical industry and the public health concerns around the misuse of prescrip



 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer